by The global Small Scale Bioreactors Market is estimated to be valued at US$ 1508.86 Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Small scale bioreactors are equipment used for cell culture, microbiological and biochemical processes that require controlled conditions. Some key advantages of small scale bioreactors are ability to handle small volume culture up to 100L, consume less floor space compared to large scale bioreactors, provide ease of operation with features like temperature sensors, stirring mechanisms and pH controllers. They find widespread applications in research, process development and clinical trial purposes for cell therapies, vaccine manufacturing and biosynthesis processes.
Market key trends:
One of the major trends driving the small scale bioreactors market growth is increasing demand for cell therapies and regenerative medicine. Growing incidence of chronic diseases and focus on developing advanced therapies have boosted research activities in cell based therapeutics. Small scale bioreactors are ideal equipment for R&D, process optimization and production of cell therapies at a small scale. Another key trend is biopharmaceutical industry’s focus on continuous manufacturing approaches which utilize fixed bed bioreactors and perfusion bioreactors. This is expected to augment adoption of scalable bioreactor technologies in the coming years. Additionally, entry of new players offering technologically advanced and customizable systems tailored for high growth applications like cell-based vaccines and stem cell research will further support market expansion over the forecast period.
Porter’s Analysis:
Threat of new entrants: Low- Medium due to capital requirement needed for R&D and equipment. Existing patents also pose a barrier.
Bargaining power of buyers: Medium- High as key players dominate the market. However, customized products increase buyer power.
Bargaining power of suppliers: Low-Medium as raw material suppliers are fragmented. Technology providers have some control.
Threat of new substitutes: Low as small scale bioreactors are niche with no close substitute. Alternatives require significant process changeover costs.
Competitive rivalry: High among key players to gain market share and acquire smaller companies for new technologies. Price competition also high for commodity products.
Key Takeaways:
The global Small Scale Bioreactors Market Growth is expected to witness high growth, exhibiting a CAGR of 10% over the forecast period, due to increasing demand for cell-based therapies and personalized drugs.
Regional anThe global Small Scale Bioreactors Market is estimated to be valued at US$ 1508.86 Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Small scale bioreactors are equipment used for cell culture, microbiological and biochemical processes that require controlled conditions. Some key advantages of small scale bioreactors are ability to handle small volume culture up to 100L, consume less floor space compared to large scale bioreactors, provide ease of operation with features like temperature sensors, stirring mechanisms and pH controllers. They find widespread applications in research, process development and clinical trial purposes for cell therapies, vaccine manufacturing and biosynthesis processes.
Market key trends:
One of the major trends driving the small scale bioreactors market growth is increasing demand for cell therapies and regenerative medicine. Growing incidence of chronic diseases and focus on developing advanced therapies have boosted research activities in cell based therapeutics. Small scale bioreactors are ideal equipment for R&D, process optimization and production of cell therapies at a small scale. Another key trend is biopharmaceutical industry’s focus on continuous manufacturing approaches which utilize fixed bed bioreactors and perfusion bioreactors. This is expected to augment adoption of scalable bioreactor technologies in the coming years. Additionally, entry of new players offering technologically advanced and customizable systems tailored for high growth applications like cell-based vaccines and stem cell research will further support market expansion over the forecast period.
Porter’s Analysis:
Threat of new entrants: Low- Medium due to capital requirement needed for R&D and equipment. Existing patents also pose a barrier.
Bargaining power of buyers: Medium- High as key players dominate the market. However, customized products increase buyer power.
Bargaining power of suppliers: Low-Medium as raw material suppliers are fragmented. Technology providers have some control.
Threat of new substitutes: Low as small scale bioreactors are niche with no close substitute. Alternatives require significant process changeover costs.
Competitive rivalry: High among key players to gain market share and acquire smaller companies for new technologies. Price competition also high for commodity products.
Key Takeaways:
The global Small Scale Bioreactors Market Growth is expected to witness high growth, exhibiting a CAGR of 10% over the forecast period, due to increasing demand for cell-based therapies and personalized drugs.
Regional analysis: North America dominates the market currently owing to early technological adoption. However, Asia Pacific is expected to grow at the fastest pace due to increasing research funding andpresence of emerging biosimilar manufacturers in China, India and South Korea.
Key players: Key players operating in the small scale bioreactors market are Merck KGaA, Danaher Corporation, Getinge AB, Sartorius AG, Thermo Fisher Scientific Inc., Lonza Group, Eppendorf AG, Miltenyi Biotec, Solaris Biotechnology Srl, Infors AG, Biosan, MicroDigital Co. Ltd., 2mag AG, MDX Biotechnik International GmbH, Esco Lifesciences Group, HiTec Zang GmbH, Hanil Scientific Inc., Adolf Kühner AG, Ori Biotech, Aglaris and AdvaBio. Merck KGaA and Danaher Corporation hold major market share. alysis: North America dominates the market currently owing to early technological adoption. However, Asia Pacific is expected to grow at the fastest pace due to increasing research funding andpresence of emerging biosimilar manufacturers in China, India and South Korea.
Key players: Key players operating in the small scale bioreactors market are Merck KGaA, Danaher Corporation, Getinge AB, Sartorius AG, Thermo Fisher Scientific Inc., Lonza Group, Eppendorf AG, Miltenyi Biotec, Solaris Biotechnology Srl, Infors AG, Biosan, MicroDigital Co. Ltd., 2mag AG, MDX Biotechnik International GmbH, Esco Lifesciences Group, HiTec Zang GmbH, Hanil Scientific Inc., Adolf Kühner AG, Ori Biotech, Aglaris and AdvaBio. Merck KGaA and Danaher Corporation hold major market share.
